The ClearCoast™ Magnetic Resonance Outcome PMS Study

Breast Cancer Clinical Trial

Official title: The ClearCoast™ Magnetic Resonance Outcome Post Marketing Surveillance Study

Status Recruiting

Clinical Trial Summary

Post Marketing Surveillance (PMS) study. Up to 93 patients undergoing breast conserving surgery will be enrolled in a prospective, single center, non-randomized controlled study, and a corresponding number of historical patients that underwent BCS will serve as the historical control group, accounting for a 1:1 ratio. All study patients and the patients in the historical control group will be required to meet the study eligibility criteria. BCS will be performed with the routine standard of care (SOC), including intra-operative methods used to improve margin assessment. In addition to SOC process, the main specimen from patients found eligible will be scanned in the ClearCoast™ system. The surgeon will utilize the information from the ClearCoast images in his margin assessments evaluation which includes the diffusion at the surface of a particular aspect (suggesting irregular tissue at the specimen's surface), and decide whether to excise additional tissue. The decision-making process including MR images interpretation and the surgical decisions will be evaluated and documented. Following procedure, routine histopathology examination will be performed accompanied by the ClearCoast optical and parametric maps. This study is a controlled design, in which subjects previously having undergone BCS by the same surgeons, will serve as the historical control group, comparing the following endpoints: - Complete surgical re-excision rate - Total excised breast tissue volume The study Control group is composed of historical data from patients previously undergone BCS, under the same site SOC surgical practice, practicing surgeons, and study eligible criteria. This allows reducing inter-group variability and bias. A device operator trained by ClearCut Medical will operate the device throughout the study.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Breast Cancer

• NCT number: NCT05458739
• Study type: Observational
• Source: Clear Cut Medical Ltd.
• Contact: Anna Levin
• Phone: +972-8-6326004
• Email: alevin@clrcut.com
• Status: Recruiting
• Start date: June 24, 2021
• Completion date: January 1, 2025